<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619848</url>
  </required_header>
  <id_info>
    <org_study_id>yuewei20221109</org_study_id>
    <nct_id>NCT05619848</nct_id>
  </id_info>
  <brief_title>Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery</brief_title>
  <acronym>RUILS</acronym>
  <official_title>Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zheng Guo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Hospital of Shanxi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of different degrees of fat infiltration on rocuronium use in&#xD;
      lumbar surgery was monitored by trapezius muscle relaxation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Select the patients who will receive posterior lumbar surgery in the Second Hospital of&#xD;
      Shanxi Medical University. According to the classification criteria of fat infiltration, it&#xD;
      will be divided into three groups: mild, moderate and severe. This study will pump and&#xD;
      titrate rocuronium bromide under the monitoring of muscle relaxation during the operation,&#xD;
      record the dosage of rocuronium bromide and the duration of pump injection, and evaluate its&#xD;
      clinical effect. Postoperative results include the use and clinical effect of rocuronium,&#xD;
      which will be counted after the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2022</start_date>
  <completion_date type="Actual">December 30, 2022</completion_date>
  <primary_completion_date type="Actual">December 27, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>use of rocuronium bromide</measure>
    <time_frame>Perioperative period</time_frame>
    <description>average dosage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The general condition of the paraspinal muscle</measure>
    <time_frame>Perioperative period</time_frame>
    <description>Fat infiltration rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Muscle relaxation satisfaction score</measure>
    <time_frame>Perioperative period</time_frame>
    <description>satisfaction score</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Spinal Stenosis Lumbar</condition>
  <arm_group>
    <arm_group_label>Mild fat infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fat infiltration rate is less than 30%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate fat infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fat infiltration rate is 30%~50%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Server fat infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fat infiltration rate is greater than 50%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium Bromide</intervention_name>
    <description>0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation</description>
    <arm_group_label>Mild fat infiltration</arm_group_label>
    <arm_group_label>Moderate fat infiltration</arm_group_label>
    <arm_group_label>Server fat infiltration</arm_group_label>
    <other_name>Midazolam, propofol, etomidate and remifentanil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age: 18-65; ASA grade I-II; no significant cardiopulmonary disease; no history of surgery&#xD;
        in the corresponding surgical area; no coagulopathy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        refusal to participate by the present experimenter; those with severe&#xD;
        cardio-cerebrovascular disease, severe hepatic and renal dysfunction; taking medications&#xD;
        affecting the neuromuscular junction; area of monitoring site for skin breakers; patients&#xD;
        with intraoperative bleeding, anaphylactic shock, or other serious complications; patients&#xD;
        requiring intraoperative neurophysiological monitoring (including sensory, motor evoked&#xD;
        potentials).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guo Zheng, Ph. D</last_name>
    <role>Study Chair</role>
    <affiliation>Second of Shanxi Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>February 14, 2023</last_update_submitted>
  <last_update_submitted_qc>February 14, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Second Hospital of Shanxi Medical University</investigator_affiliation>
    <investigator_full_name>Zheng Guo</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

